SCOLR Pharma's ANDA for 12-Hour CDT-Based Pseudoephedrine Accepted for Review by U.S. FDA

SCOLR Pharma, Inc. announcedtoday that the United States Food and Drug Administration ("FDA") has accepted for review the Company's Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on the Company's patented Controlled Delivery Technology (CDT(R)) platform.

The details can be read here.